Zoe M. Weinstein , Onchee Yu , Paige D. Wartko , Jeffrey H. Samet , Jennifer F. Bobb , Jordan M. Braciszewski , Julia H. Arnsten , Mark T. Murphy , Viviana E. Horigian , Angela L. Stotts , Donna Beers , Katharine Bradley
{"title":"由护士护理经理实施基于诊室的成瘾治疗是否会延长初级保健中的 OUD 治疗时间?PROUD 随机对照试验的二次分析。","authors":"Zoe M. Weinstein , Onchee Yu , Paige D. Wartko , Jeffrey H. Samet , Jennifer F. Bobb , Jordan M. Braciszewski , Julia H. Arnsten , Mark T. Murphy , Viviana E. Horigian , Angela L. Stotts , Donna Beers , Katharine Bradley","doi":"10.1016/j.drugalcdep.2024.112497","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Implementation of office-based addiction treatment (OBAT) by nurse care managers increases overall use of OUD medication, but it is unknown whether it increases treatment duration among treated patients.</div></div><div><h3>Methods</h3><div>The Primary Care Opioid Use Disorders Treatment (PROUD) trial was a pragmatic, cluster-randomized trial testing whether implementation of OBAT increased OUD treatment in 12 primary care clinics in 6 systems. One of 2 clinics per system was randomized to implement OBAT (intervention), the other, usual care (UC). We evaluated treatment duration for the 3 years after nurses began seeing patients at clinics randomized to intervention vs. UC. The primary sample included patients newly initiating OUD medication; the secondary sample included patients with ongoing OUD medication. The primary outcome was percentage of days with OUD medications after treatment initiation, modeled using linear generalized estimating equations (GEE). Modified Poisson GEE models assessed secondary outcomes (≥80 % of days covered, ≥6 months on treatment).</div></div><div><h3>Results</h3><div>In adjusted analyses, the mean difference between intervention and UC in percent days treated was 6.3 % (95 % CI −9.6 %, 22.1 %) in the primary sample and 2.3 % (95 % CI −36.4 %, 31.8 %) in the secondary sample. There was no significant difference in treatment duration between intervention and UC patients in either primary or secondary outcomes.</div></div><div><h3>Conclusions</h3><div>Implementation of OBAT in this trial did not measurably increase duration of medication treatment among those treated for OUD compared to UC, suggesting that benefits of OBAT, at least in this trial, largely reflect increases in treatment access.</div></div>","PeriodicalId":11322,"journal":{"name":"Drug and alcohol dependence","volume":"265 ","pages":"Article 112497"},"PeriodicalIF":3.9000,"publicationDate":"2024-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Does implementation of office based addiction treatment by a nurse care manager increase the duration of OUD treatment in primary care? A secondary analysis of the PROUD randomized control trial\",\"authors\":\"Zoe M. Weinstein , Onchee Yu , Paige D. Wartko , Jeffrey H. Samet , Jennifer F. Bobb , Jordan M. Braciszewski , Julia H. Arnsten , Mark T. Murphy , Viviana E. Horigian , Angela L. Stotts , Donna Beers , Katharine Bradley\",\"doi\":\"10.1016/j.drugalcdep.2024.112497\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Implementation of office-based addiction treatment (OBAT) by nurse care managers increases overall use of OUD medication, but it is unknown whether it increases treatment duration among treated patients.</div></div><div><h3>Methods</h3><div>The Primary Care Opioid Use Disorders Treatment (PROUD) trial was a pragmatic, cluster-randomized trial testing whether implementation of OBAT increased OUD treatment in 12 primary care clinics in 6 systems. One of 2 clinics per system was randomized to implement OBAT (intervention), the other, usual care (UC). We evaluated treatment duration for the 3 years after nurses began seeing patients at clinics randomized to intervention vs. UC. The primary sample included patients newly initiating OUD medication; the secondary sample included patients with ongoing OUD medication. The primary outcome was percentage of days with OUD medications after treatment initiation, modeled using linear generalized estimating equations (GEE). Modified Poisson GEE models assessed secondary outcomes (≥80 % of days covered, ≥6 months on treatment).</div></div><div><h3>Results</h3><div>In adjusted analyses, the mean difference between intervention and UC in percent days treated was 6.3 % (95 % CI −9.6 %, 22.1 %) in the primary sample and 2.3 % (95 % CI −36.4 %, 31.8 %) in the secondary sample. There was no significant difference in treatment duration between intervention and UC patients in either primary or secondary outcomes.</div></div><div><h3>Conclusions</h3><div>Implementation of OBAT in this trial did not measurably increase duration of medication treatment among those treated for OUD compared to UC, suggesting that benefits of OBAT, at least in this trial, largely reflect increases in treatment access.</div></div>\",\"PeriodicalId\":11322,\"journal\":{\"name\":\"Drug and alcohol dependence\",\"volume\":\"265 \",\"pages\":\"Article 112497\"},\"PeriodicalIF\":3.9000,\"publicationDate\":\"2024-11-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Drug and alcohol dependence\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0376871624014224\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug and alcohol dependence","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0376871624014224","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
Does implementation of office based addiction treatment by a nurse care manager increase the duration of OUD treatment in primary care? A secondary analysis of the PROUD randomized control trial
Background
Implementation of office-based addiction treatment (OBAT) by nurse care managers increases overall use of OUD medication, but it is unknown whether it increases treatment duration among treated patients.
Methods
The Primary Care Opioid Use Disorders Treatment (PROUD) trial was a pragmatic, cluster-randomized trial testing whether implementation of OBAT increased OUD treatment in 12 primary care clinics in 6 systems. One of 2 clinics per system was randomized to implement OBAT (intervention), the other, usual care (UC). We evaluated treatment duration for the 3 years after nurses began seeing patients at clinics randomized to intervention vs. UC. The primary sample included patients newly initiating OUD medication; the secondary sample included patients with ongoing OUD medication. The primary outcome was percentage of days with OUD medications after treatment initiation, modeled using linear generalized estimating equations (GEE). Modified Poisson GEE models assessed secondary outcomes (≥80 % of days covered, ≥6 months on treatment).
Results
In adjusted analyses, the mean difference between intervention and UC in percent days treated was 6.3 % (95 % CI −9.6 %, 22.1 %) in the primary sample and 2.3 % (95 % CI −36.4 %, 31.8 %) in the secondary sample. There was no significant difference in treatment duration between intervention and UC patients in either primary or secondary outcomes.
Conclusions
Implementation of OBAT in this trial did not measurably increase duration of medication treatment among those treated for OUD compared to UC, suggesting that benefits of OBAT, at least in this trial, largely reflect increases in treatment access.
期刊介绍:
Drug and Alcohol Dependence is an international journal devoted to publishing original research, scholarly reviews, commentaries, and policy analyses in the area of drug, alcohol and tobacco use and dependence. Articles range from studies of the chemistry of substances of abuse, their actions at molecular and cellular sites, in vitro and in vivo investigations of their biochemical, pharmacological and behavioural actions, laboratory-based and clinical research in humans, substance abuse treatment and prevention research, and studies employing methods from epidemiology, sociology, and economics.